GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » PB Ratio

Clinuvel Pharmaceuticals (ASX:CUV) PB Ratio : 4.19 (As of Jun. 05, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-05), Clinuvel Pharmaceuticals's share price is A$14.93. Clinuvel Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was A$3.56. Hence, Clinuvel Pharmaceuticals's PB Ratio of today is 4.19.

The historical rank and industry rank for Clinuvel Pharmaceuticals's PB Ratio or its related term are showing as below:

ASX:CUV' s PB Ratio Range Over the Past 10 Years
Min: 2.62   Med: 13.09   Max: 46.78
Current: 4.18

During the past 13 years, Clinuvel Pharmaceuticals's highest PB Ratio was 46.78. The lowest was 2.62. And the median was 13.09.

ASX:CUV's PB Ratio is ranked worse than
69.39% of 1310 companies
in the Biotechnology industry
Industry Median: 2.535 vs ASX:CUV: 4.18

During the past 12 months, Clinuvel Pharmaceuticals's average Book Value Per Share Growth Rate was 26.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 30.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 31.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 29.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Clinuvel Pharmaceuticals was 48.60% per year. The lowest was -31.90% per year. And the median was 1.50% per year.

Back to Basics: PB Ratio


Clinuvel Pharmaceuticals PB Ratio Historical Data

The historical data trend for Clinuvel Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals PB Ratio Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.84 17.20 15.37 5.84 5.37

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.53 5.84 7.69 5.37 4.49

Competitive Comparison of Clinuvel Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's PB Ratio falls into.



Clinuvel Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Clinuvel Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=14.93/3.564
=4.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Clinuvel Pharmaceuticals  (ASX:CUV) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Clinuvel Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (ASX:CUV) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (ASX:CUV) Headlines

No Headlines